FDA Plan To Regulate LDTs Includes Long Phase-In, Unmet-Need Exceptions

FDA said its new plan, which can’t be released as a formal draft guidance for another 60 days, would establish a more level playing field between test-kit makers and labs, while being flexible when there is not an FDA-approved alternative to an lab-developed test.